#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	18896	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2050	914.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1424	1424	C	1111	C	1034	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34448	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3597	954.9	0	.	n	.	0	T695C	SNP	695	695	T	1068	1068	C	1012	C	949	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34448	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3597	954.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1710	1710	A	1228	A	1149	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34448	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3597	954.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2344	2344	C	1149	C,T	1048,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34448	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3597	954.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2418	2418	A	1076	A	1003	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	34448	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3597	954.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2970	2970	C	1080	C	1005	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2350	folP	852	852	100.0	folP.l15.c4.ctg.1	1589	147.1	1	SNP	p	R228S	1	.	.	682	684	AGC	993	995	AGC	234;235;236	A;G,C;C	218;219,1;216	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6358	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3345	189.5	1	SNP	p	S91F	0	.	.	271	273	TCC	548	550	TCC	236;235;240	T;C,T;C	226;225,1;230	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6358	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3345	189.5	1	SNP	p	D95N	0	.	.	283	285	GAC	560	562	GAC	247;245;250	G;A,G;C	235;229,1;240	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6358	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3345	189.5	1	SNP	p	D95G	0	.	.	283	285	GAC	560	562	GAC	247;245;250	G;A,G;C	235;229,1;240	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2182	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1545	141.1	1	SNP	p	G45D	0	.	.	133	135	GGC	593	595	GGC	299;299;296	G;G;C	276;273;275	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1064	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1138	93.4	0	.	n	.	0	A197.	DEL	197	197	A	700	700	A	243	A	230	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2977	217.8	1	SNP	p	D86N	0	.	.	256	258	GAC	557	559	GAC	230;230;229	G;A;C,T	217;209;217,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2977	217.8	1	SNP	p	S87R	0	.	.	259	261	AGT	560	562	AGT	236;239;239	A;G;T	224;225;225	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2977	217.8	1	SNP	p	S87W	0	.	.	259	261	AGT	560	562	AGT	236;239;239	A;G;T	224;225;225	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2977	217.8	1	SNP	p	S87I	0	.	.	259	261	AGT	560	562	AGT	236;239;239	A;G;T	224;225;225	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6510	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2977	217.8	1	SNP	p	S88P	0	.	.	262	264	TCC	563	565	TCC	243;248;249	T;C;C	224;230;234	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5304	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2639	200.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1492	1494	GGC	247;245;244	G;G;C	231;227;225	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1226	1228	GCA	249;252;250	G;C,A;A	234;236,1;238	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1229	1231	ATC	253;252;257	A;T;C	240;241;246	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1241	1243	GTG	242;242;242	G;T;G	232;228;228	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1241	1243	GTG	242;242;242	G;T;G	232;228;228	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1745	1747	ACC	231;230;226	A;C;C	218;220;214	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1799	1801	GCG	228;226;219	G;C,G;G	201;193,1;189	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1799	1801	GCG	228;226;219	G;C,G;G	201;193,1;189	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1922	1924	GGC	201;203;205	G;G;C	187;189;192	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1931	1933	GGC	203;202;203	G;G,A;C,G	184;181,1;183,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4886	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2380	204.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1949	1951	CCG	183;185;182	C,G;CG,CGG;G	125,4;121,1;129	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7028	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3075	227.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2738	porA	1146	1146	99.83	porA.l6.c4.ctg.1	1920	142.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	582	582	C	190	C	173	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	442	444	GGA	318;318;315	G;G;A	299;294;293	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	F135L	NONSYN	403	405	TTT	703	705	CTT	291;295;297	C;T;T	275;282;282	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	R143G	NONSYN	427	429	AGA	727	729	GGA	284;287;281	G,T;G;A	267,1;270;257	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	G189S	NONSYN	565	567	GGC	865	867	AGC	285;283;281	A,G;GC,GCC;C	266,1;265,1;262	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	.	MULTIPLE	619	621	AAA	919	924	TACTAC	246;244;249;250;251;251	T;A;C;T;A;C	230;232;239;242;241;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	K208M	NONSYN	622	624	AAA	926	928	ATG	254;255;256	A;T,C;G	248;246,1;250	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	.	MULTIPLE	628	630	GAA	932	935	AAAC	249;253;253;252	A;A;A;C	242;247;246;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	N212Y	NONSYN	634	636	AAT	940	942	TAT	259;260;257	T;A;T	254;253;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	I214M	NONSYN	640	642	ATC	946	948	ATG	265;266;268	A;T;G	260;258;261	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	L218F	NONSYN	652	654	CTT	958	960	TTT	283;287;286	T;T;T	272;273;274	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	A238V	NONSYN	712	714	GCC	1018	1020	GTT	306;305;305	G;T;T	280;280;276	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	T252A	NONSYN	754	756	ACA	1060	1062	GCA	302;299;299	G;C;A	284;281;284	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	W253T	NONSYN	757	759	TGG	1063	1065	ACG	296;296;295	A;C;G	280;281;281	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1066	1068	AGG	294;292;291	A;G;G	279;278;276	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	A255V	NONSYN	763	765	GCT	1069	1071	GTT	294;297;297	G;T;T	282;280;282	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1129	1131	GTA	295;297;290	G,A;T;A	272,1;274;270	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1168	1170	ACT	321;320;316	A;C;T	285;293;287	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1174	1176	GAT	317;317;315	G;A;T	284;283;283	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1177	1179	GAT	317;312;315	G;A;T	284;280;280	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1183	1185	AAC	312;310;311	A;A;C	279;277;280	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1186	1188	CAC	316;311;308	C;A;C	285;284;283	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1291	1293	GAC	335;333;330	G;A;C	301;301;299	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	1	SNP	p	G120K	0	.	.	358	360	GGT	658	660	GGT	296;293;291	G;G;T,C,A	281;276;268,1,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	1	SNP	p	A121D	0	.	.	361	363	GCC	661	663	GCC	293;291;291	G;C;C	275;272;273	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3640	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1461	246.2	1	SNP	p	A121N	0	.	.	361	363	GCC	661	663	GCC	293;291;291	G;C;C	275;272;273	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	13436	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4844	276.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1955	1957	AAT	320;323;323	A;A;T	303;305;305	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1390	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1091	126.8	1	SNP	p	V57M	1	.	.	169	171	ATG	614	616	ATG	305;306;304	A;T;G	281;280;279	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
